Next-Generation Oncology Devices And Solutions Market Anticipated to Record Steady Gains, Advancing to $38.18 Billion by 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
What upper market value could the Next-Generation Oncology Devices And Solutions Market reach by 2030 starting from 2026 levels?
The market size for next-generation oncology devices and solutions has seen rapid expansion in recent years. It is anticipated to grow from $16.41 billion in 2025 to $19.46 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 18.6%. The historical period’s growth can be attributed to escalating global cancer incidence rates, the broadening of molecular diagnostic capabilities, the presence of advanced oncology testing tools, the proliferation of hospital-based cancer care programs, and the increasing embrace of targeted therapies.
The next-generation oncology devices and solutions market is projected to experience substantial expansion over the upcoming years. By 2030, its valuation is forecast to reach $38.19 billion, demonstrating a compound annual growth rate (CAGR) of 18.4%. This anticipated growth during the forecast period is driven by several factors, including a heightened need for tailored cancer therapies, increased capital infusion into genomic diagnostics, the proliferation of early detection initiatives, the expanding incorporation of AI into oncology processes, and developments in biomarker-driven cancer management. Key developments anticipated during this period encompass the wider embrace of precision oncology platforms, a surge in the application of NGS-based cancer diagnostics, the increasing adoption of digital pathology solutions, the wider implementation of individualized cancer treatment methods, and a sharpened emphasis on technologies for early disease detection.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24336&type=smp
Which Drivers Are Influencing Long-Term Growth In The Next-Generation Oncology Devices And Solutions Market?
The rising incidence of cancer is projected to fuel the expansion of the next-generation oncology devices and solutions market moving forward. Cancer is defined as a disease where abnormal cells multiply without control and can spread to various body parts, disrupting normal functions. The growing occurrence of cancer is primarily attributed to aging populations, as the risk of developing cancer increases with age. Next-generation oncology devices and solutions assist in managing this rising prevalence of cancer by enabling prompt detection, more precise diagnosis, and personalized treatment. For instance, in January 2024, the American Cancer Society, a US-based nonprofit organization, estimated that cancer would lead to over 611,000 fatalities in the United States, which amounts to more than 1,600 cancer-related deaths daily. Therefore, the increasing prevalence of cancer will propel the growth of the next-generation oncology devices and solutions market.
How Is The Next-Generation Oncology Devices And Solutions Market Divided Into Segments?
The next-generation oncology devices and solutions market covered in this report is segmented –
1) By Cancer Type: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), DNA Microarrays, Multiplexing, Other Technologies
3) By Application: Screening And Early Detection, Prognostics And Monitoring, Therapy Selection, Recurrence Monitoring, Other Applications
4) By End Use: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Uses
Subsegments:
1) By Breast Cancer: Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer
2) By Cervical Cancer: Squamous Cell Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma
3) By Colorectal Cancer: Colon Cancer, Rectal Cancer, Metastatic Colorectal Cancer
4) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Squamous Cell Lung Carcinoma
What Upcoming Trends Are Likely To Define The Future Path Of The Next-Generation Oncology Devices And Solutions Market?
Leading firms within the next-generation oncology devices and solutions market are prioritizing technological innovations like next-generation sequencing (NGS) target enrichment solutions. Their aim is to enhance the identification of infrequent genetic variations, boost sequencing precision, and speed up decisions regarding cancer diagnosis and treatment. Next-generation sequencing (NGS) target enrichment solutions represent methods designed to selectively isolate and amplify particular segments of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) for subsequent sequencing, which allows for a more precise and effective examination of genetic variations linked to conditions like cancer. As an illustration, in April 2025, Integrated DNA Technologies (IDT), a biotechnology firm based in the US, introduced the xGen Hybridization and Wash v3 Kit. This groundbreaking hybridization capture solution aims to expedite cancer research through optimizing next-generation sequencing (NGS) procedures. The cutting-edge kit dramatically cuts down hybridization time to a mere one hour, allowing scientists to finish sample preparation and move to sequencing within a standard workday. Furthermore, by removing the requirement for heated buffers and decreasing manual interaction by 20%, this solution proves highly compatible with automation and ideal for high-throughput uses.
Which Major Firms Are Strengthening Their Position In The Next-Generation Oncology Devices And Solutions Market?
Major companies operating in the next-generation oncology devices and solutions market are Johnson & Johnson Services Inc., Siemens AG, Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, Elekta AB, Myriad Genetics Inc., Takara Bio USA Inc., NeoGenomics Inc., Guardant Health Inc., Accuray Incorporated, SOPHiA GENETICS SA, Paige.AI Inc., Deep Bio Inc., Lucida Medical Ltd.
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Next-Generation Oncology Devices And Solutions Market?
North America was the largest region in the next-generation oncology devices and solutions market in 2025. The regions covered in the next-generation oncology devices and solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Next-Generation Oncology Devices And Solutions Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24336&type=smp
Browse Through More Reports Similar to the Global Next-Generation Oncology Devices And Solutions Market 2026, By The Business Research Company
Interventional Oncology Devices Global Market Report 2026
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Oncology Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
